India 
USA
UK
South Africa
Australia
Philippines
Germany
Netherlands
Mexico
Brazil
Canada
Mumbai | Dublin | Mexico City, September 30, 2024 – Global pharma major Lupin Limited (Lupin) today announced that it has signed a distribution agreement with Scope Ophthalmics Ireland (SCOPE) for the registration and marketing of a Moist Heat Mask, a Tea Tree Oil Eyelid Cleansing Gel and Tea Tree Oil Eyelid Wipes of the OPTASE® range, in Mexico.
The OPTASE® range is a safe, tested and expert recommended 3-step regime to help tackle the cause and symptoms of eye conditions such as Dry Eyes, Blepharitis and Meibomian Gland Dysfunction (MGD). This eye care routine comprising of Heat, Cleanse, and Hydrate, follows the TFOS* Dry Eye management strategy, as outlined in the DEWS II** publication’s staged plan.
“We are very pleased to collaborate with SCOPE and integrate a part of their OPTASE® range of products into our Ophthalmology offerings. This expansion of our Ophthalmology range reinforces our commitment to enhancing vision care for our patients, improving their quality of life,” said Dr. Fabrice Egros, President – Corporate Development and Growth Markets, Lupin.
“Through the signature of this collaboration with Lupin, SCOPE is expanding its footprint in Latin America for its OPTASE® range. Mexico is clearly a country of strategic importance for SCOPE where our innovative eyecare products, together with the strong relationships of Lupin amongst Eye Care Professionals as well as its overall credibility in the market, will certainly contribute to the success of both companies” said Tom Freyne, CEO at SCOPE.
About Lupin
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 22,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
To know more, visit www.lupin.com or follow us on LinkedIn https://www.linkedin.com/company/lupin
For further information or queries please contact –
Rajalakshmi Azariah
Vice President & Global Head – Corporate Communications, Lupin
About SCOPE
Founded in 2009, SCOPE is a healthcare company consisting of over 190 people with headquarters in Dublin and direct subsidiaries in London and New York. The company is offering a fantastic range of eyecare products
to help tackle eye conditions such as Dry Eyes, Blepharitis, Meibomian Gland Dysfunction (MGD) and Age-Related Macular Degeneration (AMD).
The OPTASE® line is sold in Ireland, UK and US markets with an excellent track record of helping patients. OPTASE® is listed within the top 10 brands across UK retailers and has secured prominent shelf space across the entire BOOTS eyecare category in the UK, achieving similar success with WALGREENS in the US.
Made strong by these successes, SCOPE is currently expanding its international network of best-in-class distributors, in efforts to expand the presence of OPTASE® across key markets in Europe, Middle East, Africa,
North and Latin America and Asia. Please visit https://optase.com/ for more information about our products.
Please visit https://optase.com/ for more information about our products.
For further information or queries please contact –
Tom Freyne
Chief Executive Officer, SCOPE
international@scopeeyecare.com